BioSpace News Archive

Phosphorus, a leading genomics firm headquartered in New York City and New Jersey, announced today that it has created two COVID-19 tests that are currently available for home delivery in the NYC metropolitan area through its in-home provider testing service.

Abcore, Inc., a leader in contract research and development of single domain antibodies announced a panel of functional therapeutic candidates they have discovered and tested for the treatment of Coronavirus Disease 2019 (COVID-19).

To ensure the proper use of antibody testing for the novel coronavirus, AACC today issued a public statement detailing the role these tests should play in the management of COVID-19 patients and in the development of public health policy

20/20 GeneSystems, Inc. announced today that it will offer in its CLIA laboratory a COVID-19 antibody test that received an Emergency Use Authorization (EUA) from the FDA on May 3.

Comprehensive MDHealthPro program includes COVID-19 testing, safety supplies, and monitoring services.

Approval based on the Phase III IMpower110 study showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced recent corporate updates and reported financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2020.

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today the closing of its public offering of 2,760,000 of its Class A common shares at a public offering price of $18.25 per share, which includes the exercise in full by the underwriters of their option to purchase additional shares.

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, today announced the appointment of Susan Rodriguez, an industry veteran with over 25 years of global pharmaceutical experience, as the company’s first chief commercial officer.